{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:04:56Z","timestamp":1759032296880},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.psc.2005.01.001","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T19:42:19Z","timestamp":1113507739000},"page":"325-347","source":"Crossref","is-referenced-by-count":34,"title":["Atypical Antipsychotics for Bipolar Disorder"],"prefix":"10.1016","volume":"28","author":[{"given":"Lakshmi N.","family":"Yatham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3\u20134","key":"10.1016\/j.psc.2005.01.001_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","article-title":"New atypical antipsychotic medications","volume":"32","author":"Jibson","year":"1998","journal-title":"J Psychiatr Res"},{"issue":"4","key":"10.1016\/j.psc.2005.01.001_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199346040-00002","article-title":"Newer antipsychotic drugs\u2014a review of their pharmacology and therapeutic potential","volume":"46","author":"Kane","year":"1993","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.psc.2005.01.001_bib3","first-page":"367","article-title":"5\u2013HT2 antagonists: a concept for the treatment of schizophrenia","volume":"3","author":"Leysen","year":"1997","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.psc.2005.01.001_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis\u2014incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.psc.2005.01.001_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic\u2014a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.psc.2005.01.001_bib6","first-page":"38","article-title":"Antipsychotic agents and bipolar disorder","volume":"59","author":"Tohen","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2005.01.001_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/070674379704200211","article-title":"Acute treatment of bipolar disorder with adjunctive risperidone in outpatients","volume":"42","author":"Ghaemi","year":"1997","journal-title":"Can J Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2005.01.001_bib8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2005.01.001_bib9","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2005.01.001_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib11","first-page":"26","article-title":"Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial","volume":"6","author":"Tohen","year":"2004","journal-title":"Bipolar Disord"},{"issue":"6","key":"10.1016\/j.psc.2005.01.001_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/appi.ajp.161.6.1057","article-title":"Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial","volume":"161","author":"Hirschfeld","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib13","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/S0924-977X(03)92033-5","article-title":"Risperidone in the treatment of acute bipolar mania: a double-blind, placebo-controlled study of 290 patients","volume":"13","author":"Khanna","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2005.01.001_bib14","doi-asserted-by":"crossref","unstructured":"Smulevich A, Khanna S, Eerdekens M, et al., Acute and continuation risperidone monotherapy in bipolar mania: a 3 week placebo controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol, in press.","DOI":"10.1016\/j.euroneuro.2004.06.003"},{"key":"10.1016\/j.psc.2005.01.001_bib15","doi-asserted-by":"crossref","unstructured":"Bowden CL, Grunze H, Mullen J, et al. A randomized double blind placebo controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry, in press.","DOI":"10.4088\/JCP.v66n0116"},{"key":"10.1016\/j.psc.2005.01.001_bib16","article-title":"Quetiapine as monotherapy for bipolar mania: a double blind randomized parellel group placebo controlled trial","author":"McIntyre","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2005.01.001_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib18","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1016\/S0924-977X(03)92104-3","article-title":"Ziprasidone in mania: a 21-day randomized, double-blind, placebo controlled trial","volume":"13","author":"Segal","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.psc.2005.01.001_bib19","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib20","first-page":"39","article-title":"Aripiprazole in acute mania: results from a second placebo-controlled study","volume":"6","author":"Hadjakis","year":"2004","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.psc.2005.01.001_bib21","article-title":"A randomized double blind placebo controlled trial of quetiapine in the treatment of bipolar I or II depression","author":"Calabrese","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib22","first-page":"204S","article-title":"Aripiprazole in the maintenance treatment of bipolar disorder","volume":"19","author":"Sanchez","year":"2004","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib23","series-title":"Brain imaging in affective disorders","article-title":"Brain imaging investigations of dopaminergic pathways in mood disorders","author":"Yatham","year":"2003"},{"issue":"3","key":"10.1016\/j.psc.2005.01.001_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions","volume":"161","author":"Tarazi","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.psc.2005.01.001_bib25","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archpsyc.56.8.705","article-title":"Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone","volume":"56","author":"Yatham","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1192\/bjp.178.5.448","article-title":"Effects of rapid tryptophan depletion on brain 5\u2013HT2 receptors: a PET study","volume":"178","author":"Yatham","year":"2001","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib27","first-page":"206S","article-title":"Randomised, double-blind, controlled data on the treatment of mania with quetiapine","volume":"19","author":"Jones","year":"2004","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2005.01.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-5618.2003.02237.x","article-title":"Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania","volume":"5","author":"Chengappa","year":"2003","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.psc.2005.01.001_bib29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1192\/bjp.148.6.723","article-title":"Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients","volume":"148","author":"Esparon","year":"1986","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2005.01.001_bib30","first-page":"176","article-title":"Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial","volume":"21","author":"Segal","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.psc.2005.01.001_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00004850-199911000-00003","article-title":"Olanzapine compared to lithium in mania: a double-blind randomized controlled trial","volume":"14","author":"Berk","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2005.01.001_bib32","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","article-title":"Olanzapine versus divalproex in the treatment of acute mania","volume":"159","author":"Tohen","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2005.01.001_bib33","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4088\/JCP.v63n1210","article-title":"A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder","volume":"63","author":"Zajecka","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2005.01.001_bib34","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/archpsyc.60.12.1218","article-title":"A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib35","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1016\/S0924-977X(03)92074-8","article-title":"Aripiprazole vs. haloperidol for maintained treatment effect in acute mania","volume":"13","author":"Bourin","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.psc.2005.01.001_bib36","unstructured":"Baker R, Zarate C Jr, Brown E, et al. A three-week comparison of olanzapine versus risperidone in the treatment of bipolar mania: improvement in manic and depressive symptoms and treatment adherence [abstract 15]. Presented at 156th American Psychiatric Association Annual Meeting. San Francisco, CA, May 17\u201322, 2003."},{"issue":"4","key":"10.1016\/j.psc.2005.01.001_bib37","first-page":"147","article-title":"Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder","volume":"57","author":"Keck","year":"1996","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2005.01.001_bib38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4088\/JCP.v62n1210","article-title":"Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania","volume":"62","author":"Miller","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 8","key":"10.1016\/j.psc.2005.01.001_bib39","first-page":"52","article-title":"Antipsychotic drug side effect issues in bipolar manic patients","volume":"61","author":"Zarate","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2005.01.001_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2005.01.001_bib41","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety","volume":"159","author":"Sachs","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib42","doi-asserted-by":"crossref","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilizer plus risperidone or placebo in the treatment of acute mania: international, double blind, randomized, controlled trial","author":"Yatham","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2005.01.001_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","article-title":"Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study","volume":"6","author":"Sachs","year":"2004","journal-title":"Bipolar Disord"},{"issue":"6","key":"10.1016\/j.psc.2005.01.001_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.jcp.0000144887.66319.2f","article-title":"Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania","volume":"24","author":"Yatham","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.psc.2005.01.001_bib45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","article-title":"A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania","volume":"41","author":"DelBello","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2005.01.001_bib46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib47","article-title":"Olanzapine versus lithium in relapse\/recurrence prevention in bipolar disorder: a randomized double blind controlled 12 month clinical trial","author":"Tohen","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2005.01.001_bib48","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1176\/appi.ajp.160.7.1263","article-title":"Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study","volume":"160","author":"Tohen","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2005.01.001_bib49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1192\/bjp.184.4.337","article-title":"Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone","volume":"184","author":"Tohen","year":"2004","journal-title":"Br J Psychiatry"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X0500002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X0500002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T23:27:06Z","timestamp":1683070026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X0500002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0193953X0500002X"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2005.01.001","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}